3/27
12:11 pm
blue
bluebird bio, Inc. (NASDAQ: BLUE) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $6.00 price target on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $6.00 price target on the stock.
3/27
12:11 pm
blue
bluebird bio, Inc. (NASDAQ: BLUE) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $6.00 price target on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $6.00 price target on the stock.
3/27
11:34 am
blue
Rating for BLUE
Medium
Report
Rating for BLUE
3/27
11:34 am
blue
Rating for BLUE
Medium
Report
Rating for BLUE
3/27
08:33 am
blue
Rating for BLUE
High
Report
Rating for BLUE
3/27
08:33 am
blue
Rating for BLUE
High
Report
Rating for BLUE
3/19
09:07 am
blue
Rating for BLUE
Low
Report
Rating for BLUE
3/19
09:07 am
blue
Rating for BLUE
Low
Report
Rating for BLUE
3/5
06:19 am
blue
Rating for BLUE
Medium
Report
Rating for BLUE
3/5
06:19 am
blue
Rating for BLUE
Medium
Report
Rating for BLUE
1/9
10:33 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) had its "market perform" rating re-affirmed by analysts at William Blair.
Low
Report
bluebird bio, Inc. (NASDAQ: BLUE) had its "market perform" rating re-affirmed by analysts at William Blair.
1/9
10:33 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) had its "market perform" rating re-affirmed by analysts at William Blair.
Low
Report
bluebird bio, Inc. (NASDAQ: BLUE) had its "market perform" rating re-affirmed by analysts at William Blair.
1/8
06:00 pm
blue
bluebird bio, Inc. (NASDAQ: BLUE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $3.00 price target on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $3.00 price target on the stock.
1/8
06:00 pm
blue
bluebird bio, Inc. (NASDAQ: BLUE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $3.00 price target on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $3.00 price target on the stock.